RARX Ra Pharmaceuticals Inc.

46.78
-0.08  -0%
Previous Close 46.86
Open 46.92
Price To Book 7.51
Market Cap 2,205,487,354
Shares 47,145,946
Volume 504,512
Short Ratio
Av. Daily Volume 711,400
Stock charts supplied by TradingView

NewsSee all news

  1. Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial

    Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced the U.S. Food and Drug Administration's (FDA) clearance of the Investigational New Drug (IND) application for the HEALEY ALS Platform Trial for the treatment of

  2. Cerevance Appoints Clinical Development Veteran Dr. Aoife Brennan to Board of Directors

    Dr. Brennan's expertise across multiple therapeutic areas and stages of drug development will prove vital as Cerevance expands its clinical CNS pipeline Cerevance, a clinical stage biopharmaceutical company advancing

  3. Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM

    Top-line results expected in the second half of 2020 Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced the initiation of dosing in its Phase 2 clinical trial of zilucoplan for the treatment of immune-mediated

  4. Ra Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    First patient dosed in the global, pivotal, Phase 3 RAISE study of zilucoplan in gMG, with top-line results expected in early 2021 On track to dose first patient in the Phase 2 trial of zilucoplan in immune-mediated

  5. Lifshitz & Miller LLP Announces Investigation of Achillion Pharmaceuticals, Inc., Anixter International Inc., Central European Media Enterprises Ltd., Digital Realty Trust, Inc., Fitbit, Inc., MutualFirst Financial, Inc., and Ra Pharmaceuticals Inc.

    NEW YORK, Nov. 4, 2019 /PRNewswire/ -- Achillion Pharmaceuticals, Inc. (ACHN) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of ACHN to Alexion

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due early 2021.
RA101495 zilucoplan
Myasthenia Gravis (MG)
Phase 1b PK data released September 26, 2018.
RA101495 SC
Atypical hemolytic uremic syndrome (aHUS)
Phase 2 trial initiation announced December 4, 2019. Data due 2H 2020.
Zilucoplan
Immune-mediated necrotizing myopathy (IMNM)
Phase 1 initiation of dosing announced August 21, 2019.
Macrocyclic peptide
Cardiovascular related

Latest News

  1. Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial

    Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced the U.S. Food and Drug Administration's (FDA) clearance of the Investigational New Drug (IND) application for the HEALEY ALS Platform Trial for the treatment of

  2. Cerevance Appoints Clinical Development Veteran Dr. Aoife Brennan to Board of Directors

    Dr. Brennan's expertise across multiple therapeutic areas and stages of drug development will prove vital as Cerevance expands its clinical CNS pipeline Cerevance, a clinical stage biopharmaceutical company advancing

  3. Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM

    Top-line results expected in the second half of 2020 Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced the initiation of dosing in its Phase 2 clinical trial of zilucoplan for the treatment of immune-mediated

  4. Ra Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    First patient dosed in the global, pivotal, Phase 3 RAISE study of zilucoplan in gMG, with top-line results expected in early 2021 On track to dose first patient in the Phase 2 trial of zilucoplan in immune-mediated

  5. Lifshitz & Miller LLP Announces Investigation of Achillion Pharmaceuticals, Inc., Anixter International Inc., Central European Media Enterprises Ltd., Digital Realty Trust, Inc., Fitbit, Inc., MutualFirst Financial, Inc., and Ra Pharmaceuticals Inc.

    NEW YORK, Nov. 4, 2019 /PRNewswire/ -- Achillion Pharmaceuticals, Inc. (ACHN) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of ACHN to Alexion

  6. UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases

    Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's rozanolixizumab, an

  7. Ra Pharmaceuticals Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for gMG

    Top-line data from the Phase 3 RAISE study expected in early 2021 Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced the initiation of dosing in the RAISE study, its global, pivotal, Phase 3 clinical trial

  8. Ra Pharmaceuticals Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for gMG

    Top-line data from the Phase 3 RAISE study expected in early 2021 Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced the initiation of dosing in the RAISE study, its global, pivotal, Phase 3 clinical trial

  9. Ra Pharmaceuticals Announces Selection for the First ALS Platform Trial by the Sean M. Healey & AMG Center for ALS at Mass General

    Multi-center platform trial sponsored by the Healey Center will simultaneously assess multiple drug regimens Zilucoplan selected by leading experts in ALS as one of the first therapeutic candidates to be tested Ra

  10. Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for Zilucoplan for the Treatment of Myasthenia Gravis

    Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to zilucoplan for the treatment of myasthenia gravis. Ra Pharma is developing